文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

青蒿琥酯治疗IgA肾病的疗效与安全性:多中心、双盲、随机、安慰剂对照试验的研究方案

Efficacy and safety of artesunate for patients with IgA nephropathy: a study protocol for a multicenter, double-blind, randomized, placebo-controlled trial.
PubMed 文献 · Trials · 2022-05-25

本研究为多中心、双盲、三组平行、安慰剂对照临床试验,计划纳入120例有进展风险的IgA肾病患者,随机分为青蒿琥酯100mg组、青蒿琥酯50mg组和安慰剂组,干预6个月后评估蛋白尿和肾功能变化,并检测血Gd-IgA1及抗Gd-IgA1水平以探索免疫机制。

要点

  • IgA肾病患者使用RAAS阻滞剂后仍常无法有效控制蛋白尿。
  • 既往研究显示抗疟药治疗肾病有较好疗效,但缺乏严格随机对照试验证实青蒿琥酯对IgA肾病的临床疗效。
  • 本试验旨在比较青蒿琥酯与安慰剂在IgA肾病患者中的效果,预期为青蒿琥酯作为治疗选择提供高质量临床证据。

核心结论

  • 目前缺乏支持青蒿琥酯治疗IgA肾病的临床证据,本试验结果预期将为青蒿琥酯作为IgA肾病治疗选择提供高质量临床证据。

研究设计与样本

  • 多中心、双盲、三组平行、安慰剂对照临床试验,计划纳入120例有进展风险的IgA肾病患者。
  • 患者随机分为青蒿琥酯100mg组、青蒿琥酯50mg组和安慰剂组。

主要发现

  • 干预6个月后测量蛋白尿和肾功能变化。
  • 检测患者血中Gd-IgA1及抗Gd-IgA1水平以探索可能的免疫机制。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: IgA nephropathy is the most common glomerular disease and is a common cause of progression to end-stage renal disease in patients with kidney diseases. Proteinuria levels are critical for the prognosis of patients with IgA nephropathy, but many patients are still unable to effectively control their proteinuria levels after receiving RAAS blockers. Antimalarial drugs have shown good efficacy in the treatment of kidney disease in previous studies; however, there have been no strictly designed randomized controlled trials to confirm the clinical efficacy of artesunate for treating IgA nephropathy patients. Therefore, we designed this clinical trial to compare the effect of artesunate versus placebo in patients with IgA nephropathy. METHODS: This study is a randomized, double-blind, three-group-parallel, placebo-controlled clinical trial. One hundred and twenty eligible IgA nephropathy patients at risk of progression will be randomly divided into the artesunate 100-mg group, artesunate 50-mg group, and placebo group. Changes in proteinuria and renal function will be measured 6 months after the intervention. The levels of Gd-IgA1 and anti-Gd-IgA1 in the patient's blood will also be tested to explore the possible immune mechanisms. DISCUSSION: Clinical evidence supporting artesunate treatment of IgA nephropathy is currently lacking, and we expect that the results of this trial will provide high-quality clinical evidence for artesunate as a treatment option for IgA nephropathy in the future. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2000038104 . Registered on 10 September 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Chen Q, Wang Z, Lv J, et al. Efficacy and safety of artesunate for patients with IgA nephropathy: a study protocol for a multicenter, double-blind, randomized, placebo-controlled trial. Trials. 2022. PMID: 35614482. doi:10.1186/s13063-022-06336-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。